Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity.

Using a variety of approaches, the authors show that this switch is mediated by the neuropeptide, sulfakinin, acting peripherally through the sulfakinin receptor 1 to regulate the expression of ...

The hypothalamus integrates neurohormonal signaling from gut and adipose tissue. Specific hypothalamic nuclei, including the dorsomedial nucleus (DMN), paraventricular nucleus (PVN) and ...

Researchers uncover a link between impaired glutathione–ascorbate metabolism and early dopamine increases in Huntington's ...

Deciphering how mammals respond to sensations through their fur could inspire further research on skin sensitivity.

重点推荐扫码下载《动物模型构建与行为评估》pdf《动物模型构建与行为评估》pdf电子版 ...

Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the ...

Attention deficit hyperactivity disorder (ADHD) affects around 1–3% of children. There is a high level of comorbidity with developmental and learning problems as well as with a variety of psychiatric ...

That means there are now four variants of the Model Y available, at least in some European countries. The configurators show the long-range version is available in Belgium, Czech Republic, Denmark, ...

Y&R’s Melody Thomas Scott Promises Nikki’s Nightmare Isn’t Over Jan 11, 2024 The Young and the Restless Y&R’s Lauralee Bell, Michael Damian, and Michelle Stafford Are Back at it Again! Oct ...